SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-185606
Filing Date
2022-06-30
Accepted
2022-06-30 08:02:33
Documents
18
Period of Report
2022-06-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d319800d8k.htm   iXBRL 8-K 36345
2 EX-5.1 d319800dex51.htm EX-5.1 11771
3 EX-10.1 d319800dex101.htm EX-10.1 146658
4 EX-10.2 d319800dex102.htm EX-10.2 137190
5 EX-10.3 d319800dex103.htm EX-10.3 168909
9 GRAPHIC g319800g0629082926204.jpg GRAPHIC 1843
10 GRAPHIC g319800g76v02.jpg GRAPHIC 10979
  Complete submission text file 0001193125-22-185606.txt   776457

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20220629.xsd EX-101.SCH 2875
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20220629_lab.xml EX-101.LAB 17236
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20220629_pre.xml EX-101.PRE 10825
12 EXTRACTED XBRL INSTANCE DOCUMENT d319800d8k_htm.xml XML 3240
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 221056549
SIC: 2834 Pharmaceutical Preparations